Boothbay Fund Management LLC Has $1.45 Million Stock Holdings in Pulmonx Co. (NASDAQ:LUNG)

Boothbay Fund Management LLC trimmed its holdings in Pulmonx Co. (NASDAQ:LUNG - Free Report) by 22.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 212,980 shares of the company's stock after selling 63,206 shares during the quarter. Boothbay Fund Management LLC owned 0.54% of Pulmonx worth $1,446,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd acquired a new stake in Pulmonx in the 4th quarter worth $46,000. 272 Capital LP bought a new stake in shares of Pulmonx in the 3rd quarter worth approximately $48,000. Stifel Financial Corp acquired a new stake in shares of Pulmonx during the 4th quarter worth approximately $81,000. SG Americas Securities LLC increased its position in shares of Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock valued at $106,000 after purchasing an additional 3,310 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Pulmonx by 48.7% in the fourth quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock valued at $125,000 after purchasing an additional 6,033 shares in the last quarter. Institutional investors own 91.04% of the company's stock.

Insider Activity

In other news, CEO Steven S. Williamson sold 27,689 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total value of $197,699.46. Following the transaction, the chief executive officer now owns 194,342 shares of the company's stock, valued at approximately $1,387,601.88. This trade represents a 12.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the sale, the director now owns 1,011,974 shares of the company's stock, valued at approximately $8,379,144.72. This represents a 5.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 145,660 shares of company stock valued at $1,128,484 over the last three months. 6.80% of the stock is owned by insiders.

Pulmonx Price Performance

LUNG remained flat at $3.77 during trading on Friday. The company's stock had a trading volume of 902,554 shares, compared to its average volume of 320,380. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $151.73 million, a PE ratio of -2.62 and a beta of 0.61. The company's 50 day moving average price is $6.53 and its 200 day moving average price is $6.55. Pulmonx Co. has a 52-week low of $3.61 and a 52-week high of $10.01.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The business had revenue of $22.54 million during the quarter, compared to analysts' expectations of $22.03 million. On average, sell-side analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LUNG. Morgan Stanley started coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued an "equal weight" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $17.00 price target on shares of Pulmonx in a research report on Thursday. Jefferies Financial Group began coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a "buy" rating for the company. Canaccord Genuity Group lowered their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, Citigroup initiated coverage on Pulmonx in a research report on Monday, March 10th. They set a "buy" rating for the company. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Pulmonx presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.07.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.